Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any infantile liver failure in which the cause of the disease is a mutation in the LARS gene.
Features include sometimes findings: Full cheeks, Long toe, Delayed gross motor development, and Inner ear hearing loss (sensorineural hearing impairment) and others. 20 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 4 | Hepatic steatosis, Enlarged liver (hepatomegaly), Acute hepatic failure |
LARS1 encodes leucyl-tRNA synthetase 1 (1,176 aa). Aminoacyl-tRNA synthetase that catalyzes the specific attachment of leucine to its cognate tRNA (tRNA(Leu)). Highest expression in Cells Cultured fibroblasts (104.3 TPM) and Cells EBV-transformed lymphocytes (72.1 TPM).
Infantile liver failure syndrome 1 is associated with mutations in the LARS1 gene on chromosome 5.
LARS1 is classified as a druggable target (Druggable Genome and Enzyme categories) with score 52.2.
Genetic testing for LARS1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for infantile liver failure syndrome 1 has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for infantile liver failure syndrome 1.
5 publications have been identified in PubMed for infantile liver failure syndrome 1. Research spans Case Report / Case Series (40%), Diagnostic / Biomarker (20%), and Basic Science / Preclinical (20%).
Fuchs A (2025). [PMID: 40400350](https://pubmed.ncbi.nlm.nih.gov/40400350/). *Clin Genet*. [Case Report / Case Series]
Li SY (2024). [PMID: 38844943](https://pubmed.ncbi.nlm.nih.gov/38844943/). *Orphanet J Rare Dis*. [Epidemiology / Natural History]
Uehara T (2024). [PMID: 38923116](https://pubmed.ncbi.nlm.nih.gov/38923116/). *Am J Med Genet A*. [Case Report / Case Series]
Hammann N (2024). [PMID: 38951950](https://pubmed.ncbi.nlm.nih.gov/38951950/). *J Inherit Metab Dis*. [Diagnostic / Biomarker]
Inoue M (2024). [PMID: 38807157](https://pubmed.ncbi.nlm.nih.gov/38807157/). *Orphanet J Rare Dis*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 18, 2026, 8:41 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Blood and immune system
3 |
Abnormality of the coagulation cascade, Low red blood cell count (anemia), Macrocytic anemia |
Brain and nerves | 3 | Seizure, Global developmental delay, Delayed gross motor development |
Muscles | 3 | Low muscle tone (hypotonia), Generalized hypotonia, Delayed gross motor development |
Arms and legs | 2 | Long toe, Long fingers |
Head and neck | 1 | Microcephaly |
Growth and development | 1 | Failure to thrive |
Ears | 1 | Inner ear hearing loss (sensorineural hearing impairment) |
Lab test results | 1 | Elevated circulating hepatic transaminase concentration |